Just a moment, the page is loading...

JANUVIA/JANUMET HTA Submission(Germany)

JANUVIA/JANUMET HTA Submission(Germany)

Dr. Rainer Woker

MSD Sharp & Dohme GmbH


04 November 2016

Every new drug has to be evaluated by a health technology process. Within this process the new compound will be compared to the standard of care therapy in this indication. In Germany a pharmaceutical company has to submit a dossier for this benefit assessment to the Federal Joint Committee (G-BA). That was done by MSD in 2013 for Sitagliptin in combination with Metformin for the treatment of Type-II-Diabetes.

In the dossier Sitagliptin/Metformin was compared with the appropriate comparator Sulfonylurea/Metformin. The G-BA certified that Sitagliptin/Metformin has an additional benefit for the patients. The G-BA conclusion was restricted in a timely manner till July 1st 2016. The reason for the restriction was missing long term data.

Therefore, MSD Germany resubmitted an updated version of the dossier on July 1. All available evidence was provided to the G-BA. The study HARMONY 3 meets the inclusion criteria for this benefit assessment. On October 4 the benefit assessment was published (Link: https://www.g-ba.de/downloads/92-975-1595/2016-07-01_Nutzenbewertung-IQWiG_Sitagliptin-Metformin-D-246.pdf). It was stated that there is a lack of evidence. Subgroup analyses by metformin dose at baseline for HARMONY 3 are missing.

Therefore we request for data of HARMONY 3 by October 21, 2016. The objective is to show the applicability of the results to the German healthcare context.

[{ "PostingID": 2416, "Title": "GSK-GLP112753", "Description": "A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus" }]

Statistical Analysis Plan